Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer’s Lyrica Will Undergo Phase IV Vision, Nerve Impairment Studies

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer also commits to a post-marketing study of pregabalin’s propensity to induce CYP-enzyme metabolism. Lyrica is undergoing controlled substance scheduling by DEA. The European Medicines Agency says that study data suggest pregabalin is not a “prototypic” risk for abuse when compared to diazepam.

You may also be interested in...



Lyrica's DEA Scheduling Will Not Hold Back Sales, Pfizer Says

Pfizer CEO McKinnell says "the level of scheduling we're anticipating...should not have a significant impact on our opportunity" with Lyrica. Pfizer will work to lift DEA's scheduling for Lyrica, Senior VP Feczko says.

Lyrica's DEA Scheduling Will Not Hold Back Sales, Pfizer Says

Pfizer CEO McKinnell says "the level of scheduling we're anticipating...should not have a significant impact on our opportunity" with Lyrica. Pfizer will work to lift DEA's scheduling for Lyrica, Senior VP Feczko says.

Pfizer Lyrica Undergoing Controlled Substance Scheduling At DEA

FDA clears pregabalin for management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia. The Neurontin follow-on compound remains "approvable" for the adjunctive treatment of partial seizures in adults with epilepsy.

Topics

UsernamePublicRestriction

Register

OM007016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel